Linxi Zhu graduated from China Pharmaceutical University in June 2018 with BS degrees in pharmacy. She completed a MS in the Department of Pharmaceutics at the University of Washington in 2020. During her MS career, Linxi worked with Dr. Rodney Ho to develop gemcitabine and paclitaxel drug combination nanoparticles targeted to ICAM-1 on breast cancer cells. In Spring and Summer 2021, Linxi worked as a research scientist in the Ho lab to investigate whether the dynamic light scattering is considered a reliable analysis method for a GMP manufactured nanoparticle product. Linxi joined the Department of Medicinal Chemistry in Autumn 2021 and the Xu Lab in Spring 2022. Her project focuses on the impact of CYPs polymorphisms on benzalkonium chloride metabolism. Outside of academics, Linxi enjoys anime, watching soccer and basketball games, painting and reading.